Eli Lilly and Company
The purpose of the study is to assess if a single dose of LY3981314 is safe in participants with autoimmune hepatitis. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body The study will last about 30 weeks.
Inclusion Criteria: * Have a confirmed diagnosis of autoimmune hepatitis (AIH) for greater than or equal to (≥) 6 months according to American Association for the Study of Liver Diseases diagnostic criteria (Appendix 8, Section 10.8) * Have alanine aminotransferase (ALT) greater than (\>) 1.5x upper limit of normal (ULN) to less than (\<) 5x ULN * Have elevated soluble FAS (sFAS) based on Sponsor predetermined threshold * Be on a stable immunosuppressive medication regimen for AIH with no dose changes or weaning of treatment for ≥8 weeks prior to screening, and no anticipated medication adjus…
Administered SC
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.